University of Missouri School of Medicine MU Health School of Medicine
News Divider
            


Mark McDonald has Duchenne muscular dystrophy, the most common lethal genetic disease diagnosed in children. His father Robert McDonald, MD '88, finds hope in MU's gene therapy research, which has received a new $2.1 million grant from the National Institutes of Health.


Getting to the Heart of Muscular Dystrophy


Gene therapy researcher awarded NIH grant
to protect cardiac muscles from deadly disease


Children with Duchenne muscular dystrophy (DMD) face a future of rapidly weakening muscles, which usually leads to death by respiratory or cardiac failure before their 30th birthday. While researchers are hopeful that gene therapy could eventually evolve into an effective treatment, few have targeted the heart of the problem as much as Dongsheng Duan, PhD.

Duan hopes a new $2.1 million grant he received from the National Institutes of Health will help him develop a treatment that prevents heart muscles from weakening as a result of DMD. As many as 40 percent of patients with the inherited disorder die from heart failure because their weakened cardiac muscles can't pump enough blood to sustain life.

Children with DMD, which is often seen in boys, experience weakening of both skeletal muscle and heart muscle due to a defective gene for dystrophin, a type of muscle protein. Researchers have developed a synthetic dystrophin gene that has shown to be effective in treating skeletal muscle, but Duan's findings published in the journal Molecular Therapy show that cardiac muscle requires different treatment. In fact, tests in an animal model have shown that treating skeletal muscle alone while leaving cardiac muscle untreated can lead to serious complications: Stronger skeletal muscles mean patients can be more physically active, which requires a stronger heart to pump blood throughout the body.

"We've demonstrated that the gene therapy that works for the skeletal muscle doesn't necessarily work for the heart," Duan said. "If we want a more comprehensive treatment, we cannot ignore how the disease affects cardiac muscle."

Duan's lab has analyzed data on thousands of patients with DMD to identify common patterns in deletions on the dystrophin gene that could have led to heart-specific muscle weakness. Now the researcher is developing a new synthetic gene that he hopes will comprehensively treat muscles weakened by DMD.

"We're developing this gene based on what we already know about skeletal muscle, so it will not only be perfectly functional for skeletal muscle but also therapeutic for heart muscle," said Duan, a Margaret Proctor Mulligan Distinguished Professor in Medical Research in MU's Department of Molecular Microbiology and Immunology.

Duan plans to evaluate the newly developed gene in dystrophic mouse and dog models. With funding from additional NIH grants, Duan's team is developing viral vectors for carrying the most important parts of the therapeutic genes to diseased muscle cells. The therapy-carrying viruses will be injected directly into the blood system or the muscles. Following therapy, researchers will perform a series of tests to evaluate the strength of the heart muscle and the effect of the treatment.

"Researchers are more advanced in their understanding of Duchenne muscular dystrophy when it comes to skeletal muscle, but cardiac and skeletal muscle need to be simultaneously treated in patients," Duan said. "This is just the beginning of research on the heart muscle."

While still being tested in labs, Duan's proposed therapy gives hope to parents like Robert McDonald, MD, of Jefferson City, Mo. His son Mark was diagnosed with DMD when the boy was 2 years old. Dr. McDonald now serves on the board of directors and the therapeutics committee for Parent Project Muscular Dystrophy, the largest nonprofit organization focused on DMD. Parent Project has also awarded funds for Duan's research.

"He is one of the most valuable people trying to find a solution for DMD," McDonald said. "Parents like me are looking to scientists like him to someday help our children grow up to be men, and hopefully old men."




Missouri Health News Network

Divider

News and Events

Drinking and Sleep MU Researchers Find Alcohol Interferes with Sleep
Study finds alcohol affects the body's sleep homeostasis and can cause insomnia

Research Day MU Announces Awards at Health Sciences Research Day
Event features projects from student and physician researchers

Binge Drinking MU Researchers Identify Epigenetic Changes Caused by Binge Drinking
Overconsumption of alcohol triggers inflammatory response in the liver

Dermatology Gala Gala To Celebrate Five Decades Of Dermatology At MU
Dermatology residency program began in 1963

HIV MU Researchers Discover Protein's Ability To Inhibit HIV Release
TIM-family proteins also play role in Ebola and other viral infections

McAndrew $2.4 Million Gift Funds Endowed Chair in Cancer Research
Support inspired by experience with cancer center and student at MU

Lai MU Researchers Find Gene Therapy Protects Mice from Heart Condition
The condition is a leading cause of death for those with Duchenne muscular dystrophy

White Coat Ceremony MU's Expanded Medical Class Receives White Coats at Ceremony
Event marks start of professional journey for 104 students

Belden Interactive E-Book Aims to Improve Electronic Health Records
E-book provides guidelines for usability of EHRs

Delafontaine Tulane Cardiovascular Researcher Named School of Medicine Dean
Patrice Delafontaine, MD, is accomplished physician-scientist, educator, administrator




Media Relations
University of Missouri Health System
One Hospital Drive, DC028.00
Columbia, MO 65212
24/7 on-call pager: (573) 876-0708

Mary Jenkins
jenkinsmg@health.missouri.edu
(573) 882-7299

Jeff Hoelscher
hoelscherj@health.missouri.edu
(573) 884-1608

Derek Thompson
thompsonder@health.missouri.edu
(573) 882-3323


Web Communications
University of Missouri Health System
One Hospital Drive, MA204G, DC018.00
Columbia, MO 65212
(573) 884-0298

Rich Gleba
glebar@health.missouri.edu
(573) 884-0298

Laura Gerding, APR
gerdingla@health.missouri.edu
(573) 882-9193

Velvet Hasner
hasnerv@health.missouri.edu
(573) 884-1115

Mike Muin
muinm@health.missouri.edu
(573) 884-7541



Printer Friendly
Follow us on Twitter!   Facebook   YouTube Videos   Instagram   Pinterest  
Website created and maintained by the Office of Communications.
Contact the MU School of Medicine.
Revised: April 27, 2013 - Copyright © 2014 - Curators of the University of Missouri. All rights reserved. DMCA and other copyright information. An equal opportunity/access/affirmative action/pro-disabled and veteran employer.